Teva UK and Closed Loop Medicine announce strategic partnership to advance development of personalised medicines
Castleford and London: Teva UK Limited and Closed Loop Medicine Ltd have announced a strategic partnership to advance the development of personalised medicine.
Ubiquigent and Debiopharm Enter Agreement to Support USP1 Inhibitor Programme for Debio 0432
Project will be a demonstration of how Ubiquigent’s DUB-centric platform can support the development of DUB inhibitors all the way from discovery through to clinical development.
ArgusEye introduces AugaOne to accelerate downstream bioprocess development
AugaOne sensor system provides specific, real-time, and automated data to reduce mAb process development time New sensor will be exhibited at the Bioprocessing Summit, 18-21 March 2024, booth 66Linköping, Sweden, 21 March 2024:
Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies
Arrayjet’s patented spot-on-spot microarray screening technology is available for customers to adopt in-house and via Arrayjet’s CRO/CMO services Immunome signs deal to use Arrayjet platform in its in-house screening operationsEdinburgh,
Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement
CRISPR/Cas9 genome editing technology contributes to the expansion of the creation of novel disease model
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming Phase IIb study following successful Phase Ib/IIa studyCambridgeshire and Belfast, UK: Exploristics, a world-leading provider of biosimulat
Metrion Biosciences strengthens team with three key appointments
Clare Rutty promoted to CFO, Sue Peffer appointed Head of Marketing, Leanne Clarke appointed HR Officer.
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully support continued clinical development of EXN407 into the CLEAR-DM Phase IIb studySolasCure publishes Phase IIa Clinical Trial Report in leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the Phase IIa trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase Wound Gel in patients suffering from chronic wounBio-Rad launches Vericheck ddPCR Replication Competent Lentivirus and Replication Competent AAV Kits for cell and gene therapy production
Rapid, Sensitive, and Validated Detection of Viral Replication Genes Using Droplet Digital™ PCR During Cell and Gene Therapy Production
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
Company’s synthetic affinity reagents are antibody alternatives designed to advance the speed, safety, and efficiency of manufacturing at scale, making advanced therapies more accessible to patients. Investment led by Mercia Ventures, with Calculus Capital and Angel investors alsClosed Loop Medicine demonstrates application of novel drug plus software product for personalized treatment of hypertension
Study published in JAHA validates use of proprietary technology to identify personalized dose regimen, leading to improved blood pressure control and exceptionally high adherence in hypertension patients Findings will guide the Company’s strategy to expand portfolio of differentiYokogawa introduces CellVoyager High-Content Analysis System CQ3000
New system enables advanced analysis of live cell cultures with high-definition, high-speed 3D imaging Expands Yokogawa’s CellVoyager range, comprising its imaging devices and analysis software, to support research applications from basic science to drug discovery scEnhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer
Appointment forms part of ongoing plans for continued development of the GenLink3D genomics platform and formation of strategic commercial and academic partnerships
CN Bio appoints Joseph Parisi as US Director of Sales to support accelerated growth in key OOC market
Cambridge, UK, 30 January 2024: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single- and multi-organ microphysiological systems (MPS), announces the appointment of Joseph Parisi as US Director of Sales.
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansionAsimov launches LV Edge Packaging System to optimize lentivirus production
Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.
PlaqueTec and the Babraham Institute collaborate on phenotypic screen of coronary artery blood
Collaboration to develop a bespoke cell phenotyping assay for human blood Project aims to investigate cell types present in coronary artery samples from patients with CAD participating in PlaqueTec’s BIOPATTERN trial Assay will be available as a service in the BabrahamCalluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases
· Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics · Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases
ERS Genomics and StemSight sign CRISPR/Cas9 license agreement
License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindnessDublin, Ireland, and Tampere, Finland - ERS Genomics Limited (‘ERS’), the CRISPR licensing Company,
Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge.
DeepMirror launches early access programme for its intuitive molecular drug design software
Cambridge, UK - DeepMirror, a University of Cambridge spin-out company developing intuitive design software for the discovery of novel therapeutic drugs, announces the launch of its Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months. The software allows users to tap into AI-driven insights to improve and…
Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution
Biotage® PeptiPEC high-throughput kits facilitate fast and low solvent consumption solution for plate-based peptide purification Partnership complements Gyros’ PurePep® EasyClean technology offering with an automated solution for advanced discovOptibrium’s Quantum Mechanics and Machine Learning Methods Predict Routes of Drug Metabolism
Peer-reviewed study published in Xenobiotica describes an innovative new method that predicts the routes and products of Phase I and II metabolism with high sensitivity and greater precision than other approaches